https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » Acute myeloid leukemia
Trovagene updates on acute myeloid leukemia trial for Onvansertib

Trovagene updates on acute myeloid leukemia trial for Onvansertib

Trovagene, a California-based cancer research company, said that it has wrapped up the second dosing cohort of the Onvansertib-decitabine combination, in a phase 1b/2 acute myeloid leukemia trial. Onvansertib is said to be a highly-selective oral Polo-like Kinase 1 (PLK1) inhibitor. Designed to be orally administered, Onvansertib has a 24-hour drug half-life. According to Trovagene, […]

Cantex acute myeloid leukemia drug CX-01gets FDA fast track designation

Cantex Pharmaceuticals, a Florida-based biotech company, has secured the fast track designation for its acute myeloid leukemia drug CX-01 from the US Food and Drug Administration (FDA). The FDA fast track designation for CX-01 is for the treatment of patients, aged over 60, who are being subjected to induction therapy for newly diagnosed acute myeloid […]

Continue reading …
Tolero, AbbVie to explore venetoclax alvocidib combo for AML

Tolero Pharmaceuticals said that its cyclin-dependent kinase 9 (CDK9) inhibitor alvocidib will be combined with AbbVie leukemia drug venetoclax to evaluate their potential in their treatment of relapsed/refractory acute myeloid leukemia (AML). In this regard, the two companies have entered into a clinical research collaboration while retaining full commercial rights for their respective drugs. According […]

Continue reading …
FDA approves Agios’ Tibsovo for acute myeloid leukemia treatment

Tibsovo (ivosidenib) developed by Agios Pharmaceuticals has been approved by the US Food and Drug Administration (FDA) for acute myeloid leukemia treatment in patients with a specific genetic mutation and whose condition relapsed or is refractory. The Agios AML drug has been indicated to be used with an FDA-approved companion diagnostic that will detect specific […]

Continue reading …
Ivosidenib FDA approval : Agios blood cancer drug approved for AML

Ivosidenib FDA approval : The US Food and Drug Administration (FDA) has approved Agios Pharmaceuticals’ blood cancer drug TIBSOVO (ivosidenib) for the treatment of acute myeloid leukemia (AML). The ivosidenib FDA approval is for the treatment of adult patients whose condition is relapsed or refractory and who are prone to isocitrate dehydrogenase-1 (IDH1) mutation as […]

Continue reading …
Cyclacel’s blood cancer drug for elderly patients, sapacitabine fails in phase 3 trial

The blood cancer drug for elderly patients, sapacitabine (CYC682) developed by New Jersey based Cyclacel Pharmaceuticals has failed to meet its objective in a crucial phase 3 study. An orally-administered nucleoside analogue, sapacitabine did not meet the primary endpoint which was statistically significant improvement in overall survival (OS) in the phase 3 trial named as […]

Continue reading …